Auscann Group Holdings Ltd To Present on CPAT-01 Phase2A Results Transcript
Hi, I'm Dr. Margaret Curtis, Head of Research and Development for CannPal Animal Therapeutics. Thanks for taking the time to hear the latest results for CPAT-01, our lead drug candidate derived from medical cannabis currently in the development for the management of pain and inflammation in dogs.
I will take you briefly over our development pathway and the study design for our first study using CPAT-01 in client-owned animals. I will go over the details of what the veterinarians saw, as well as the owners and highlights of the results from our biomarker assessments. I will conclude on how this study contributes to the development of CPAT-01 and where we will be going to from here.
It has been an exciting and productive journey for CPAT-01, an oral cannabinoid treatment for dogs. Early work focused on confirming the pharmacokinetic profile and assessing the impact of different concentrations of CBD relative to THC to select our lead candidate cannabinoid ratio. During this earliest phase, gene expression
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
